胃苏颗粒联合雷贝拉唑钠肠溶片治疗慢性非萎缩性胃炎临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R573.3

基金项目:


Clinical Study on Weisu Granules Combined with Rabeprazole Sodium for Chronic Non-Atrophic Gastritis
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察胃苏颗粒联合雷贝拉唑钠肠溶片治疗慢性非萎缩性胃炎的临床疗效。方法:将90 例慢 性非萎缩性胃炎患者按随机数字表法分为对照组与治疗组各45 例,对照组采取雷贝拉唑钠肠溶片治疗,治疗 组在对照组的基础上联合胃苏颗粒治疗。比较2 组治疗前后疼痛视觉模拟评分法(VAS) 评分、日常生活能力 量表(ADL) 评分、前列腺素E2 (PGE2)、表皮细胞生长因子(EGF)、炎症因子[肿瘤坏死因子-α(TNF-α)、 白细胞介素-6(IL-6)]、胃泌素(GAS)、胃动素(MTL) 水平变化,同时分析2 组临床疗效及不良反应发生 率。结果:治疗组总有效率为95.56%,对照组为80.00%,2 组比较,差异有统计学意义(P<0.05)。治疗 前,2 组VAS、ADL 评分比较,差异无统计学意义(P>0.05)。治疗后,2 组VAS 评分较治疗前降低(P< 0.05),ADL 评分较治疗前升高(P<0.05);且治疗组2 项评分改善较对照组更显著(P<0.05)。治疗前,2 组血 清TNF-α、IL-6 水平比较,差异无统计学意义(P>0.05);治疗后,2 组TNF-α、IL-6 水平均较治疗前降 低(P<0.05),且治疗组TNF-α、IL-6 水平均低于对照组(P<0.05)。治疗前,2 组GAS、MTL 水平比较, 差异无统计学意义(P>0.05);治疗后,2 组GAS、MTL 水平均较治疗前升高(P<0.05),且治疗组GAS、 MTL 水平均高于对照组(P<0.05)。治疗前,2 组PGE2、EGF 水平比较,差异无统计学意义(P>0.05)。治疗 后,2 组PGE2 水平较治疗前升高(P<0.05),EGF 水平较治疗前降低(P<0.05);且治疗组PGE2 水平高于对 照组(P<0.05),EGF 水平低于对照组(P<0.05)。治疗组不良反应发生率为4.44%,明显低于对照组 17.78%,2 组比较,差异有统计学意义(P<0.05)。结论:胃苏颗粒联合雷贝拉唑钠肠溶片治疗慢性非萎缩性 胃炎疗效显著,可促进GAS、MTL 分泌,降低疼痛程度和炎症反应,提高日常生活能力,且不良反应发生率 相对较低。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Weisu Granules combined with Rabeprazole Sodium for chronic non-atrophic gastritis (CAG). Methods:A total of 90 cases of CAG patients were divided into the control group and the treatment group according to the random number table method , with 45 cases in each group. The control group was treated with Rabeprazole Sodium Enteric-Coated Tablets, and the treatment group was additionally treated with Weisu Granules based on the treatment of the control group. The changes in the scores of Visual Analogue Scale (VAS) and Activity of Daily Living Scale (ADL), and the levels of prostaglandin E2 (PGE2), epidermal growth factor (EGF), inflammatory factors [tumor necrosis factor- α (TNF- α), interleukin- 6 (IL- 6)], gastrin (GAS), and motilin (MTL) were compared between the two groups before treatment and after treatment. Clinical effects and the incidence of adverse reactions were analyzed in the two groups. Results:The total effective rate was 95.56% in the treatment group and 80.00% in the control group,the difference being significant between the two groups (P<0.05). Before treatment,there was no significant difference being found in the comparison of scores of VAS and ADL between the two groups (P>0.05). After treatment,VAS scores in the two groups were decreased when compared with those before treatment (P<0.05),and ADL scores were increased when compared with those before treatment (P<0.05); the improvement of the two scores in the treatment group was more significant than that in the control group (P<0.05). Before treatment, there was no significant difference being found in the comparison of levels of TNF-α and IL-6 in serum between the two groups (P> 0.05). After treatment,the levels of TNF- α and IL- 6 in the two groups were decreased when compared with those before treatment (P<0.05), and the levels of TNF- α and IL- 6 in the treatment group were lower than those in the control group (P<0.05). Before treatment,there was no significant difference being found in the comparison of levels of gastrin and motilin between the two groups (P>0.05). After treatment, the levels of GAS and MTL in the two groups were increased when compared with those before treatment (P<0.05),and the two levels in the treatment group were higher than those in the control group (P<0.05). Before treatment,there was no significant difference being found in the comparison of levels of PGE2 and EGF between the two groups (P>0.05). After treatment,levels of PGE2 in the two groups were increased when compared with those before treatment (P<0.05),and EGF levels were decreased when compared with those before treatment (P<0.05);the level of PGE2 in the treatment group was higher than that in the control group (P<0.05),and EGF level was lower than that in the control group (P<0.05). The incidence of adverse reactions was 4.44% in the treatment group,significantly lower than that of 17.78% in the control group,the difference being significant (P<0.05). Conclusion:Weisu Granules combined with Rabeprazole Sodium Enteric-Coated Tablets has a significant curative effect in the treatment of CAG,and can increase GAS and MTL,reduce pain degree and inflammatory responses,and improve activities of daliyliving with a relatively low incidence of adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

张春华,李娟,唐凯.胃苏颗粒联合雷贝拉唑钠肠溶片治疗慢性非萎缩性胃炎临床研究[J].新中医,2023,55(8):69-73

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-04-25
  • 出版日期:
文章二维码